Catalog No.S2875 Synonyms: R-93877
Molecular Weight(MW): 367.87
Prucalopride is a selective, high affinity 5-HT receptor agonist for 5-HT4A and 5-HT4B receptor with Ki of 2.5 nM and 8 nM, respectively, exhibits >290-fold selectivity against other 5-HT receptor subtypes.
1 Customer Review
Comparison of gastrointestinal transit tracked over 12 h for animals treated with different concentrations of loperamide, prucalopride, and for DMSO-treated/control animals (dotted line) at 4 h (black), 9 h (light grey), and 12 h (dark grey) (n = 6-13 animals per group). (A) Transit scores for 6 solid beads, and (B) Location of the leading bead. Transit scoring is detailed in Table 1. Asterisks indicate the significance of each treatment relative to controls (*p < 0.05; **p < 0.01). Data show mean ± SEM.
Neurogastroenterol Motil, 2016, 28(8):1241-51.. Prucalopride purchased from Selleck.
Purity & Quality Control
Choose Selective 5-HT Receptor Inhibitors
|Description||Prucalopride is a selective, high affinity 5-HT receptor agonist for 5-HT4A and 5-HT4B receptor with Ki of 2.5 nM and 8 nM, respectively, exhibits >290-fold selectivity against other 5-HT receptor subtypes.|
Prucalopride induces contractions in a concentration-dependent manner with pEC50 of 7.5. Prucalopride (1 mM) significantly amplifies the rebound contraction of the guinea-pig proximal colon after electrical field stimulation. Prucalopride induces relaxation of the rat oesophagus preparation of rat oesophagus tunica muscularis mucosae with pEC50 of 7.8, yielding a monophasic concentration–response curve. 
|In vivo||Complete bowel movements per week is 30.9% of those receiving 2 mg of Prucalopride and 28.4% of those receiving 4 mg of Prucalopride, as compared with 12.0% in the placebo group. 47.3% of patients receiving 2 mg of Prucalopride and 46.6% of those receiving 4 mg of Prucalopride has an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group. Prucalopride (2 mg or 4 mg) significantly improves all other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms.  Prucalopride (4 mg daily) accelerates overall gastric emptying and small bowel transit in patients with constipation without a rectal evacuation disorder. Prucalopride (4 mg daily) tends to accelerate overall colonic transit with significantly faster overall colonic transit and ascending colon emptying.  Higher proportions of patients on prucalopride 2 mg (19.5%), 4 mg (23.6%) has three or more spontaneous complete bowel movements(SCBM)/week compared with placebo (9.6%). Prucalopride also significantly improves secondary efficacy and quality of life endpoints, including the proportion of patients with an increase of one or more SCBM/week, evacuation completeness, perceived disease severity and treatment effectiveness and quality of life.  Prucalopride alters colonic contractile motility patterns in a dose-dependent fashion by stimulating high-amplitude clustered contractions in the proximal colon and by inhibiting contractile activity in the distal colon of fasted dogs. Prucalopride also causes a dose-dependent decrease in the time to the first giant migrating contraction (GMC); at higher doses of prucalopride, the first GMC generally occurres within the first half-hour after treatment. |
-  Briejer MR, et al. Eur J Pharmacol, 2001, 423(1), 71-83.
-  Camilleri M, et al. N Engl J Med, 2008, 358(22), 2344-2354.
-  Bouras EP, et al. Gastroenterology, 2001, 120(2), 354-360.
|In vitro||DMSO||60 mg/mL (163.1 mM)|
|Ethanol||38 mg/mL (103.29 mM)|
|Water||slightly soluble or insoluble|
|In vivo||Add solvents individually and in order:
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02947269||Not yet recruiting||Postoperative Ileus|Colorectal Surgery|Postoperative Complications||University of Auckland, New Zealand||January 2017||Phase 3|
|NCT02806206||Not yet recruiting||Gastrointestinal Hemorrhage|Crohn Disease|Celiac Disease|Intestinal Diseases|Inflammatory Bowel Diseases||University of British Columbia||July 2016||Phase 4|
|NCT02781493||Not yet recruiting||Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp||Shandong University|Binzhou Peoples Hospital|Taian Peoples Hospital|Linyi Peoples Hospital||June 2016||Phase 4|
|NCT02538367||Completed||Functional Constipation||Yuhan Corporation||August 2015||Phase 1|Phase 2|
|NCT02228616||Completed||Constipation||Xian-Janssen Pharmaceutical Ltd.||October 2014||Phase 4|
|NCT02425774||Recruiting||Postoperative Ileus||Katholieke Universiteit Leuven|Universitaire Ziekenhuizen Leuven||July 2014||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.